1
A Study of U3-1402 in Subjects With Metastatic Breast Cancer
Condition(s):Metastatic Breast CancerLast Updated:January 12, 2022Recruiting
U3-1402: 9 Clinical Trials
Hide Studies Not Open or Pending
2
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Condition(s):Metastatic Colorectal CancerLast Updated:April 15, 2022Terminated
3
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Condition(s):Breast CancerLast Updated:April 4, 2022Recruiting
4
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Condition(s):Metastatic Breast CancerLast Updated:July 16, 2021Recruiting
5
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Condition(s):Metastatic Breast CancerLast Updated:November 16, 2021Active, not recruiting
6
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Condition(s):Non-Small Cell Lung Cancer (NSCLC)Last Updated:April 28, 2022Active, not recruiting
7
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Condition(s):Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorLast Updated:May 11, 2022Recruiting
8
Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Condition(s):Non-Small Cell Lung Cancer (NSCLC)Last Updated:November 5, 2021Recruiting
9
A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Condition(s):Nonsquamous Non-small Cell Lung Cancer; EGFR L858RLast Updated:April 21, 2022Recruiting